Sanofi SA (EPA:SAN) has been given a €85.00 ($101.19) price objective by equities researchers at J P Morgan Chase & Co in a research note issued to investors on Thursday. The brokerage presently has a “neutral” rating on the stock.

Other equities analysts have also issued research reports about the company. UBS AG set a €82.00 ($97.62) price target on Sanofi SA and gave the stock a “neutral” rating in a research report on Wednesday, June 14th. Sanford C. Bernstein set a €90.00 ($107.14) price target on Sanofi SA and gave the stock a “neutral” rating in a research report on Monday, July 31st. S&P Global set a €90.00 ($107.14) price target on Sanofi SA and gave the stock a “neutral” rating in a research report on Monday, July 31st. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) price target on Sanofi SA and gave the stock a “neutral” rating in a research report on Wednesday, May 24th. Finally, Jefferies Group LLC set a €87.00 ($103.57) price target on Sanofi SA and gave the stock a “neutral” rating in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the stock. Sanofi SA currently has an average rating of “Hold” and a consensus target price of €87.88 ($104.61).

Sanofi SA (EPA SAN) traded down 0.84% during mid-day trading on Thursday, hitting €81.37. 5,934,268 shares of the stock traded hands. Sanofi SA has a 52-week low of €24.55 and a 52-week high of €82.67. The firm has a market cap of €102.18 billion and a P/E ratio of 11.35. The firm’s 50-day moving average is €26.12 and its 200 day moving average is €25.99.

ILLEGAL ACTIVITY NOTICE: “Sanofi SA (SAN) Given a €85.00 Price Target at J P Morgan Chase & Co” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/17/sanofi-sa-san-given-a-85-00-price-target-at-j-p-morgan-chase-co.html.

About Sanofi SA

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.